Scarica l'app Stockscreener
9.00
2.04%
0.18
Pre-mercato:
9.35
0.35
+3.89%
Precedente Chiudi:
$8.82
Aprire:
$8.8
Volume 24 ore:
1.79M
Relative Volume:
0.85
Capitalizzazione di mercato:
$937.92M
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-3.0405
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
+1.12%
1M Prestazione:
-18.03%
6M Prestazione:
-36.08%
1 anno Prestazione:
-56.44%
Intervallo 1D:
$8.77
$9.495
Intervallo di 1 settimana:
$8.74
$9.561
Portata 52W:
$8.58
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
9.00 | 937.92M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Learn to Evaluate (SNDX) using the Charts - news.stocktradersdaily.com
Syndax Pharmaceuticals’ SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7%What's Next? - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax reports publication of revumenib data from BEAT AML trial - Yahoo Finance
SNDX Trial Data Shows Promising Results in AML Treatment | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in - GlobeNewswire
Syndax Announces Publication of Revumenib Data from the BEAT AML - GuruFocus
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 - The Manila Times
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Announces Publication of Revumenib Data from the - GlobeNewswire
Clinical Trial: New AML Drug Achieves 100% MRD Negativity, Doubles Survival vs Standard Care - Stock Titan
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of ... - Eagle-Tribune
Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj - The Pharma Letter
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refra - GuruFocus
SNDX: New Data Revealed from Syndax's AUGMENT-101 Trial | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - The Manila Times
Syndax Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Canada
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 32,653 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - MSN
Syndax Pharmaceuticals at Jefferies Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Li - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Nuveen Asset Management LLC - MarketBeat
Voloridge Investment Management LLC Acquires Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wellington Management Group LLP Has $55.98 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.9% HigherShould You Buy? - MarketBeat
84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.91 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP - MarketBeat
Syndax Announces Participation in June Investor Conferences | SN - GuruFocus
Syndax Announces Participation in June Investor Conferences - The Manila Times
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Syndax Pharmaceuticals Inc Azioni (SNDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Huber Martin H. Jr. | Director |
May 19 '25 |
Buy |
8.99 |
5,000 |
44,950 |
79,000 |
| Katkin Keith | Director |
May 19 '25 |
Buy |
9.11 |
10,000 |
91,120 |
100,000 |
| Metzger Michael A | Chief Executive Officer |
Mar 14 '25 |
Option Exercise |
7.20 |
6,074 |
43,733 |
306,195 |
| Metzger Michael A | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
7.20 |
7,814 |
56,261 |
307,935 |
| Metzger Michael A | Chief Executive Officer |
Mar 04 '25 |
Sale |
15.05 |
7,814 |
117,564 |
300,121 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):